Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
1 other identifier
interventional
19
0 countries
N/A
Brief Summary
Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2017
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedFirst Submitted
Initial submission to the registry
May 10, 2017
CompletedFirst Posted
Study publicly available on registry
May 11, 2017
CompletedMay 11, 2017
May 1, 2017
3 months
May 10, 2017
May 10, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Change in serum uric acid
Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy
at three months of Febuxostat 40 milligrams Tablet therapy
Interventions
Febuxostat 40 milligramsTablet every other day for 3 months
Eligibility Criteria
You may qualify if:
- Age above 18 years
- Hemodialysis patient
- Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)
You may not qualify if:
- Patient currently and/or recently received drugs for hyperuricemia within the last three months
- Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Benha Universitylead
- New Jeddah Clinic Hospitalcollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD. - Lecturer at Internal Medicine Department- Faculty of Medicine
Study Record Dates
First Submitted
May 10, 2017
First Posted
May 11, 2017
Study Start
January 1, 2017
Primary Completion
April 1, 2017
Study Completion
May 1, 2017
Last Updated
May 11, 2017
Record last verified: 2017-05
Data Sharing
- IPD Sharing
- Will not share